Literature DB >> 10716353

Parameters that affect in vitro splicing of bovine papillomavirus type 1 late pre-mRNAs.

Z M Zheng1, C C Baker.   

Abstract

During the course of study on regulated viral pre-mRNA splicing, an in vitro RNA splicing assay was developed to analyze how an exonic splicing enhancer stimulates splicing of bovine papillomavirus type 1 (BPV-1) late pre-mRNAs. The optimal concentration of HeLa nuclear extract (HNE) in a standard RNA splicing reaction depends on the individual substrate pre-mRNA. Splicing of a BPV-1 late pre-mRNA required 40% HNE and 2 h incubation at 30 degrees C. Higher HNE was detrimental to splicing and longer incubation times lead to RNA degradation. In the reaction containing 40% EDTA-treated HNE, 1.5-3.0 mM Mg2+ or 3 mM Mn2+, but not Co2+, were required to catalyze an efficient splicing reaction. Surprisingly, EDTA-untreated HNE in the absence of exogenous Mg2+ catalyzed very efficiently splicing of the RNA. Addition of Mg2+ from 0.1 to 0.5 mM, only enhanced slightly the splicing in EDTA-untreated HNE and excessive Mg2+ concentration (above 1.5 mM) in the reaction resulted in production of aberrant splicing products or intermediates. In contrast, addition of Mn2+ to EDTA-untreated HNE severely suppressed splicing. In addition, it was observed that the RNA transcribed from vector sequences downstream of the polylinker region of pSP72 vector, when connected to the 3' terminus of chimeric Drosophila doublesex-BPV-1 SE1 pre-mRNAs, suppressed dramatically splicing. RNA transcribed from the pSP72 polylinker region, when supplied in trans, also suppressed splicing. These results suggest that a DNA template used to make RNA transcripts should avoid these sequences as much as possible.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716353     DOI: 10.1016/s0166-0934(99)00172-x

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Kaposi's sarcoma-associated herpesvirus K8beta is derived from a spliced intermediate of K8 pre-mRNA and antagonizes K8alpha (K-bZIP) to induce p21 and p53 and blocks K8alpha-CDK2 interaction.

Authors:  Koji Yamanegi; Shuang Tang; Zhi-Ming Zheng
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Utilization of the bovine papillomavirus type 1 late-stage-specific nucleotide 3605 3' splice site is modulated by a novel exonic bipartite regulator but not by an intronic purine-rich element.

Authors:  Z M Zheng; E S Reid; C C Baker
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Optimization of a weak 3' splice site counteracts the function of a bovine papillomavirus type 1 exonic splicing suppressor in vitro and in vivo.

Authors:  Z M Zheng; J Quintero; E S Reid; C Gocke; C C Baker
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Human papillomavirus type 16 E2 and E6 are RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs with suboptimal splice sites.

Authors:  Sohrab Bodaghi; Rong Jia; Zhi-Ming Zheng
Journal:  Virology       Date:  2009-02-01       Impact factor: 3.616

5.  Kaposi's sarcoma-associated herpesvirus ORF57 functions as a viral splicing factor and promotes expression of intron-containing viral lytic genes in spliceosome-mediated RNA splicing.

Authors:  Vladimir Majerciak; Koji Yamanegi; Eric Allemand; Michael Kruhlak; Adrian R Krainer; Zhi-Ming Zheng
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

6.  Serine/Arginine-Rich Splicing Factor 3 and Heterogeneous Nuclear Ribonucleoprotein A1 Regulate Alternative RNA Splicing and Gene Expression of Human Papillomavirus 18 through Two Functionally Distinguishable cis Elements.

Authors:  Masahiko Ajiro; Shuang Tang; John Doorbar; Zhi-Ming Zheng
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

7.  Intron definition and a branch site adenosine at nt 385 control RNA splicing of HPV16 E6*I and E7 expression.

Authors:  Masahiko Ajiro; Rong Jia; Lifang Zhang; Xuefeng Liu; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

8.  Vemurafenib-resistant BRAF selects alternative branch points different from its wild-type BRAF in intron 8 for RNA splicing.

Authors:  Masahiko Ajiro; Zhi-Ming Zheng
Journal:  Cell Biosci       Date:  2015-12-21       Impact factor: 7.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.